Galvus Tablet 50 mg is an oral antidiabetic medication used to manage type 2 diabetes mellitus. It belongs to the class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors. It helps to regulate blood sugar levels by enhancing the body's natural ability to lower blood glucose.
Galvus Tablet 50 mg is primarily used for:
| Brand Name | Galvus |
|---|---|
| Type | Tablet |
| Weight | 50 mg |
| Generic | Vildagliptin |
| Manufacturer | Novartis (Bangladesh) Ltd. |
| Available in | English বাংলা |
Galvus Tablet 50 mg works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). This enzyme breaks down incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). By inhibiting DPP-4, Galvus Tablet 50 mg increases the levels of these incretin hormones, which enhances insulin secretion from the pancreas and decreases glucagon levels, leading to improved blood glucose control.
The effects of Galvus Tablet 50 mg can be observed within a few weeks of starting treatment. Optimal blood glucose control is generally achieved within 1 to 2 months of consistent use. The time to see significant improvements in glycemic control can vary depending on individual patient factors and the presence of other antidiabetic medications.
Galvus Tablet 50 mg is rapidly absorbed after oral administration. Peak plasma concentrations are reached approximately 1 to 2 hours post-ingestion. The bioavailability of Galvus Tablet 50 mg is around 85%, meaning that a significant proportion of the administered dose is available for therapeutic effect.
Galvus Tablet 50 mg is primarily eliminated through the kidneys. Approximately 70% of the dose is excreted unchanged in the urine. A small proportion is metabolized in the liver and subsequently excreted in the urine.
The typical starting dose of Galvus Tablet 50 mg is 50 mg taken orally once or twice daily. Depending on the patient's response and tolerance, the dose may be adjusted. The maximum recommended dose is 100 mg per day, usually divided into two doses. Dosage adjustments are required for patients with renal impairment.
Galvus Tablet 50 mg should be taken orally, with or without food. It is usually prescribed as a part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and exercise. Consistent daily administration is necessary for optimal glycemic control.
Common side effects of Galvus Tablet 50 mg include:
Less common but serious side effects can include:
Overdose of Galvus Tablet 50 mg is rare but may lead to severe hypoglycemia if used with other hypoglycemic agents. Symptoms of hypoglycemia include sweating, shaking, confusion, and dizziness. In cases of overdose, supportive care and monitoring of blood glucose levels are recommended.
Precautions include:
Galvus Tablet 50 mg may interact with other medications, including:
Galvus Tablet 50 mg should be used with caution in patients with:
Potential drug interactions include:
There are no specific food interactions with Galvus Tablet 50 mg. It can be taken with or without food. However, maintaining a balanced diet and consistent carbohydrate intake is important for managing blood glucose levels effectively.
The safety of Galvus Tablet 50 mg during pregnancy has not been well established. It should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Alternative antidiabetic treatments may be preferred during pregnancy.
It is not known whether Galvus Tablet 50 mg is excreted in breast milk. Caution should be exercised when using Galvus Tablet 50 mg in lactating women, and a decision should be made whether to discontinue the drug or discontinue breastfeeding based on the drug's importance to the mother.
In case of acute overdose, hypoglycemia is a major concern. Symptoms may include confusion, dizziness, and sweating. Immediate treatment with glucose or glucagon may be required, and medical attention should be sought to manage symptoms and ensure safety.
Galvus Tablet 50 mg is contraindicated in patients with:
Take Galvus Tablet 50 mg exactly as prescribed by your healthcare provider. Do not alter the dose without consulting your healthcare provider. Regular monitoring of blood glucose levels and renal function is essential during treatment.
Store Galvus Tablet 50 mg at room temperature, between 15°C and 30°C (59°F and 86°F). Keep the medication in its original container, tightly closed, and out of reach of children. Avoid exposure to moisture and excessive heat.
The volume of distribution of Galvus Tablet 50 mg is approximately 71 liters, indicating that it is widely distributed in the body tissues.
The elimination half-life of Galvus Tablet 50 mg is approximately 2.5 hours. This relatively short half-life supports the need for regular dosing to maintain therapeutic levels.
Galvus Tablet 50 mg is primarily cleared through the kidneys. The clearance rate is influenced by renal function, with adjustments needed for patients with impaired renal function to prevent accumulation and potential adverse effects.
See in details version Galvus Tablet 50 mg also Galvus Tablet 50 mg in bangla